[an error occurred while processing this directive]
BBC News
watch One-Minute World News
Last Updated: Tuesday, 18 May, 2004, 10:15 GMT 11:15 UK
Celltech accepts takeover offer
Petri dish, tests - Corbis
The UK's biggest biotech firm, Celltech, has agreed to be taken over by the Belgian drugmaker UCB.

The agreed bid is for 550 pence a share, compared with Monday's closing price of 430.5p, and values Celltech at 1.5bn.

The deal will create Europe's second-largest bio-pharmaceutical firm, with Denmark's Novo Nordisk at number one.

Celltech employs about 1,900 people and had a turnover of more than 350m during its last financial year.

'Fair value'

UCB said it had also agreed to license the worldwide rights for Celltech's rheumatoid arthritis treatment CDP 870.

Celltech's chairman, Dr Peter Fellner, said the offer represented "fair value" for the company's shareholders.

Celltech reported pre-tax, pre-exceptional, profits of 52.2m for 2003, although after allowing for exceptional costs of 98.3m following acquisitions it had a pre-tax loss of 53.9m.

Roch Doliveux, chief executive of UCB Pharma, said the firm was looking forward to working with Celltech "to transform Celltech's and UCB's very promising pipeline into commercial value for our shareholders".

Samir Devani, an analyst at Code Securities, told the Reuters news agency that UCB's deal to license CDP 870 would put off any possible rival bids.

"There's no reason for anybody to come in [with a rival bid] if the rights to CDP 870 have already been signed over," he said.

Celltech hopes for drug progress
16 Mar 04  |  Business
Celltech profits surge
19 Aug 03  |  Business

The BBC is not responsible for the content of external internet sites


News Front Page | Africa | Americas | Asia-Pacific | Europe | Middle East | South Asia
UK | Business | Entertainment | Science/Nature | Technology | Health
Have Your Say | In Pictures | Week at a Glance | Country Profiles | In Depth | Programmes
Americas Africa Europe Middle East South Asia Asia Pacific